| Added by | mollevi |
|---|---|
| Group name | EquipeCG |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA. Electronic address: kwon.eugene@mayo.edu. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Institut Gustave Roussy, University of Paris-Sud, Villejuif, France. Institut Gustave Roussy, Villejuif, France. VU University Medical Centre, Amsterdam, Netherlands. Vienna General Hospital, Medical University Vienna, Vienna, Austria. Institut Bergonie, Bordeaux, France; CHU Caremeau, Nimes, France. Centro Medico Austral, Buenos Aires, Argentina. Centre Jean Perrin, Clermont-Ferrand, France. St John of God Hospital, Subiaco, WA, Australia. University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. Hospital de Caridade de Ijui, Ijui, Brazil. Nottingham University Hospital, Nottingham, UK. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. Hospital Britanico de Buenos Aires, Buenos Aires, Argentina. Herlev Hospital, Herlev, Denmark. Odense University Hospital, Odense, Denmark. University of Texas MD Anderson Cancer Center, Houston, TX, USA. Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA. Bristol-Myers Squibb, Wallingford, CT, USA. Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. alt-title: The Lancet. Oncology number: 7 accession-num: 24831977 |
| Tags | _EndnoteXML import |
| Date Added | 2018/07/20 - 10:05:58 |
| Date Modified | 2018/07/20 - 10:05:58 |
| Parent item | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial |
Institut de Recherche en Cancérologie de
